Polypharmacy and adverse drug reactions in Japanese elderly taking antihypertensives: a retrospective database study
Izumi Sato,1 Manabu Akazawa2
1Department of Epidemiology and Statistics, Graduate School of Medicine, The University of Tokyo Tokyo, Japan; 2Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan
Background: The concomitant use of multiple medications by elderly patients with hypertension is a relatively common and growing phenomenon in Japan. This has been attributed to several factors, including treatment guidelines recommending prescription of multiple medications and a continuing increase in the elderly population with multiple comorbidities.
Objective: This study was aimed at investigating the association between polypharmacy, defined as the concomitant use of five or more medications, and risk of adverse drug reaction (ADR) in elderly Japanese hypertensive patients to examine the hypothesis that risk of ADR increases with the administration of an increasing number of co-medications.
Methods: Using a retrospective cohort design, the data regarding all hypertensive patients aged 65 years or older were extracted from the Risk/Benefit Assessment of Drugs – Analysis and Response Council antihypertensive medication database. The data were reviewed for classification of patients into one of three groups according to drug use at the initiation of therapy – a monotherapy group composed of patients who had taken the investigated drug only, a co-medication group composed of patients who had taken the investigated drug and a maximum of three other medications, and a polypharmacy group composed of patients who had taken the investigated drug and four or more other medications – and determination of the number of ADR events experienced. Estimated rate ratios (RRs) and 95% confidence intervals (CIs) were calculated using a Poisson regression model adjusted for drug category and patient age and sex. Various sensitivity analyses were performed to confirm the robustness of the study findings.
Results: Of 61,661 elderly Japanese patients (men, 41.8%; 75 years or older, 35.1%) registered in the database, 2491 patients (4.0%) experienced a total of 3144 ADR events during the study period. The rate of ADR per 10,000 person-days was 2.0 for the monotherapy group, 5.1 for the co-medication group, and 8.6 for the polypharmacy group. After adjusting for age, sex, and initial antihypertensive therapy, the RR was estimated at 2.4 (95% CI, 2.2–2.6) for the co-medication group and 4.3 (95% CI, 3.8–4.8) for the polypharmacy group, when compared with the monotherapy group.
Conclusion: The use of polypharmacy increases the risk of ADR among elderly Japanese patients with hypertension, calling for regular medication review to eliminate the administration of unnecessary co-medications.
Keywords: adverse drug reaction, antihypertensive, elderly, pharmacoepidemiology, polypharmacy
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins
Benucci M, Li Gobbi F , Meacci F, Manfredi M, Infantino M, Severino M, Testi S, Sarzi-Puttini P, Ricci C, Atzeni F
Published Date: 17 February 2015
Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells [Corrigendum]
Yu L, Wang XL, Zhu D, Ding WC, Wang LM, Zhang CL, Jiang XH, Shen H, Liao SJ, Ma D, Hu Z, Wang H
Published Date: 4 February 2015
Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups
Assaad-Khalil SH, Najem R, Sison J, Kitchlew AR, Cho BL, Ueng KC, DiTommaso S, Shete A
Published Date: 21 January 2015
Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer
Zhao XJ, Chen Q, Liu W, Li YS, Tang HB, Liu XH, Yang XL
Published Date: 30 December 2014
Photothermal cancer therapy using graphitic carbon–coated magnetic particles prepared by one-pot synthesis
Lee HJ, Sanetuntikul J, Choi ES, Lee BR, Kim JH, Kim E, Shanmugam S
Published Date: 30 December 2014
Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights
Schalper KA, Venur VA, Velcheti V
Published Date: 23 December 2014
Published Date: 12 December 2014
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Noreddin AM, Elkhatib WF, Cunnion KM, Zhanel GG
Published Date: 7 October 2011
Racial differences in tumor necrosis factor-α-induced endothelial microparticles and interleukin-6 production
Brown MD, Feairheller DL, Thakkar S, Veerabhadrappa P, Park JY
Published Date: 26 August 2011
Weibo Cai, Ting Gao, Hao Hong, Jiangtao Sun
Published Date: 19 September 2008